Vamorolone shows glucocorticoid activity without immunosuppression in Phase 1 study.

Catalyst Pharmaceuticals announced topline results from a Phase 1 clinical study of vamorolone, a novel medicine for rare and difficult-to-treat diseases. The study demonstrated on-target glucocorticoid activity without significant immunosuppression at clinical doses, showcasing vamorolone's balanced corticosteroid profile. The results support further development of vamorolone for the treatment of chronic autoimmune and inflammatory diseases.

Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX) has announced topline results from a Phase 1 clinical study of vamorolone, a novel corticosteroid with dissociative properties, indicating its potential for treating rare and difficult-to-treat diseases. The study demonstrated that vamorolone exhibited on-target glucocorticoid activity without significant immunosuppression at clinical doses, highlighting its balanced corticosteroid profile. These findings support the further development of vamorolone for chronic autoimmune and inflammatory diseases.

Vamorolone, marketed as AGAMREE in the United States, is a first-in-class oral medication approved for the treatment of Duchenne Muscular Dystrophy (DMD) in patients aged two years and older. The drug’s unique mechanism of action involves differential effects on glucocorticoid and mineralocorticoid receptors, potentially offering comparable efficacy to traditional corticosteroids with a better-tolerated side effect profile.

The Phase 1 study results align with previous findings from the VISION-DMD trial, which showed that vamorolone maintained motor function improvements over 48 weeks and demonstrated a favorable safety profile compared to prednisone. The most commonly reported adverse events in clinical trials include cushingoid features, vomiting, and vitamin D deficiency, generally of mild to moderate severity.

AGAMREE received U.S. FDA approval on October 26, 2023, and is eligible for seven years of orphan drug exclusivity. The drug also holds Orphan Drug and Rare Pediatric Disease designations, and has issued and pending patents that could provide protection until 2040. In Europe, AGAMREE has received Promising Innovative Medicine (PIM) status from the UK MHRA for DMD.

The Phase 1 results reinforce Catalyst’s strategy of developing and commercializing innovative therapies for rare diseases. With a focus on patient-centric care, Catalyst continues to expand its portfolio, including FIRDAPSE® and FYCOMPA®, to address unmet medical needs in neuromuscular and neurological disorders.